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Summary
Double hit lymphoma (DHL) and double protein-expressing (MYC and BCL2) lymphomas (DPL) 
fare poorly with R-CHOP; consolidative autologous stem cell transplant (ASCT) may improve 
outcomes. S9704, a phase III randomized study of CHOP +/−R with or without ASCT allows 
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evaluation of intensive consolidation. Immunohistochemical analysis identified 27 of 198 patients 
(13.6%) with MYC IHC overexpression and 20 (74%) harboring concurrent BCL2 overexpression. 
Four had DHL and 16 had DPL only. With median follow-up 127 months, there is a trend favoring 
outcomes after consolidative ASCT in DPL and MYC protein overexpressing patients, whereas all 
DHL patients have died irrespective of ASCT.
Keywords
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Background
Diffuse large B-cell lymphoma (DLBCL), the prototype of aggressive Non-Hodgkin 
lymphoma (NHL), has clinical and biologic variants with diverse clinical outcomes1. 
Historically, dual translocations of MYC and BCL2 (or BCL6) “double hit lymphoma” 
(DHL) are associated with a rapid clinical course and poor survival2. DHL is fortunately 
uncommon, with reported frequencies of 2–8% among DLBCL patients3. The commercial 
availability of a reliable stain for MYC protein overexpression4 has furthered evaluation of 
MYC’s role in lymphomas, although the definition of overexpression varies5. In general, 
dual MYC and BCL protein overexpression (DPL) is also associated with a poor prognosis 
and is more common than DHL5.
SWOG S9704 was a phase III randomized study of aggressive NHL treated with CHOP +/
−R for 5 cycles followed by either 3 additional cycles of CHOP +/−R or one additional cycle 
of induction chemotherapy followed by autologous stem cell transplant (ASCT) 
consolidation. ASCT improved progression free survival (PFS) for high-risk patients, but 
biologic subsets were not separately evaluated in the initial analysis6. While we have 
previously evaluated the impact of histopathology and MYC protein expression7 the current 
report includes an updated dataset with an emphasis on the impact of transplant.
Methods
This randomized intergroup trial included eligible patients 15 to 65 years with biopsy-
confirmed aggressive non- Hodgkin’s lymphoma, high-intermediate or high-risk age 
adjusted IPI (aaIPI)8. Stratification factors and detailed treatment information have been 
published6.
All cases had central pathology review. 198 available patient samples were tested for MYC 
protein overexpression. BCL2 IHC (≥30% positive cells), COO classification (germinal 
center: GC versus non-germinal center: non-GC per Hans algorithm9), and FISH for MYC 
were performed in all MYC IHC positive cases with sufficient tissue. FISH for BCL2 
rearrangements was performed in cases with a MYC rearrangement (Figure 1). A descriptive 
analysis of outcomes was performed using clinical annotations through SWOG statistical 
center, and review of S9704 database. Tissue microarrays, immunohistochemistry, FISH 
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studies, statistical analysis were performed as previously described7 with additional details 
available (Supplemental Material).
Results
As previously published, there were no significant differences between randomized groups, 
and early ASCT improved PFS for high-intermediate-risk or high-risk disease with 2-year 
PFS of 69% and 55%, respectively. Among 370 eligible patients from S9704, 260 had 
DLBCL or B-cell lymphoma, unclassifiable, with features intermediate between DLBCL 
and BL (BCLU) and 198 cases had available tissue for the current analysis. Twenty-seven 
MYC IHC positive patients were identified. Among 27 MYC IHC positive patients, 8 
received CHOP. 16/27 had concurrent BCL2 overexpression by IHC and were classified as 
DPL. Four patients had DHL with associated dual protein expression. Seven of 27 were 
MYC positive only by IHC without DPL or DHL (Figure 1).
Patient Characteristics and Outcomes
Median age, aaIPI, bulky disease and elevated LDH were similar between MYC IHC 
positive and DPL patients. COO was performed in 17/27 MYC IHC positive patients and 11 
had GC and 6 had non-GC DLBCL. In the DPL group, COO was evaluable in 10/16 patients 
and 4 had GC and 6 had non-GC DLBCL (Supplemental Table 1).
The median follow-up is 127 months (range, 93.8–158.2 months). In an analysis of actual 
treatment received, two year PFS for the transplant and non-transplant group was 63% and 
16%, respectively (p*=0.02; Figure 2a). Median PFS was 6 months (95% CI: 4.5–9.0) for no 
transplant, and 31 months for transplant (95% CI; 6.3, not reached). Two-year OS for 
transplant and non-transplant group was 63% and 16%, respectively (p*=0.04; Figure 2b). 
Similarly, in the DPL group, 9 patients in the no transplant group and 3 patients in the 
transplant group have progressed or died; the median PFS was 7 months (95% CI: 2.8, 13.9) 
versus 31 months (95% CI: 16.3, not reached) for non-transplanted versus transplanted 
patients, respectively. The Kaplan Meier estimate of 2 year PFS, OS for transplant and non-
transplant groups were 60% and 18%, respectively (p*=0.19 for PFS and p*=0.25 for OS; 
Figures 2c and 2d).
In MYC positive patients, 19/27 patients could be randomized, with disease progression 
precluding randomization in others. 11/19 patients did not receive transplant, and their 2 
year PFS was 27% compared to 8/19 patients who received transplant with a 2 year PFS of 
63% (p*=0.11; Figure S1a); similarly, the 2-year OS for the non-transplant group was 27% 
and the transplant group was 63%, respectively (p*=0.17; Figure S1b). Among patients with 
DPL, 12/16 patients were randomized; the 2-year PFS and OS was 29% for the non-
transplant group and 60% for the transplant group, respectively (p*=0.43 for PFS and 
p*=0.53 for OS); (Figure S1c and S1d). p* (two-sided Logrank).
Three of four DHL patients survived to randomization, and one was randomized to 
transplant. All progressed and died with a median overall survival of 5.9 months (95% CI: 
5.3, 6.7 months).
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DHL and DPL are associated with inferior outcomes following standard 
chemoimmunotherapy10. When correlating DHL with COO, DHL appears associated with 
the GC type of DLBCL whereas several groups have observed that non-GC DLBCL is 
enriched for DPL, and provocatively suggest that the major underlying reason for poor 
outcomes in non-GC DLBCL is due to MYC and BCL2 protein overexpression11. Our 
analysis sought to determine the frequency of DHL and DPL among a MYC IHC positive 
transplant-eligible population, and to evaluate the impact of consolidative ASCT in a 
prospective dataset. The key observations are the rarity of both DHL and DPL in younger 
patients, the universally dismal outcome of DHL, and the suggestion that consolidative 
ASCT may be useful in DPL patients.
The overall incidence of MYC IHC positivity was low in our population, identifying only 
27/198 (13.6%) cases with available tissue. This is in contrast to other retrospective series in 
which the incidence of MYC IHC positivity occurs in 30–50% of cases5. Similarly, we had 4 
cases of DHL and 16 cases (8% of the available samples) of DPL. This discrepancy may be 
due to differences in the median age across series and additional cases that were MYC IHC 
negative may not have been captured. The median age of S9704 patients was 51 years 
(range, 18–66 years), reflecting a transplant-eligible population. In contrast, most 
retrospective DHL and DPL series demonstrate that over half of the patients with DPL are 
older than 60 years, and some report a median age of 71 years12. Thus, despite enrolling 
high IPI and advanced stage patients in S9704, the low frequency of DPL in our series 
suggests a strong correlation with advanced age that may impact future trials in this 
population.
Despite general consensus that dual MYC and BCL2 protein expression confer a negative 
prognosis in DLBCL, the optimal IHC cut-point defining overexpression is not uniform5, 13. 
The definition of BCL2 expression was 30% in the Hans Classifier9; however, the largest 
series to study DPL used a cut-point of 70%12. We used a cutoff of 30%; despite this 
conservative cut-point, we still identified a relatively small sample size.
A critical, as yet unanswered, question in DHL and DPL is the optimal initial therapy and 
whether or not consolidative ASCT improves outcomes. Most data are retrospective series or 
registry databases, and focused primarily on DHL rather than DPL. These series collectively 
show that R-CHOP is insufficient therapy with median overall survival of 10 months or less; 
Compared to augmented or intensified regimens, the use of R-CHOP appears inferior14. All 
four patients with DHL in our series have died of disease with a median survival of six 
months despite consolidative ASCT in one, emphasizing the role of an effective induction.
The role of high dose therapy in DPL and DHL is undefined. Some have proposed that 
achievement of CR determines outcome rather than consolidative ASCT15. However, these 
studies evaluated DHL and not DPL; our small analysis thus offers one of the first reports to 
address consolidative transplant in DPL. Of note, the median age of the 16 DPL patients was 
56.3 years, placing these patients among the oldest of the entire initial series that had a 
median age of 51 years. Furthermore, only 12 could be randomized, mainly due to 
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progressive disease during induction. While numbers are small and confidence intervals 
wide, DPL patients randomized to ASCT had superior outcomes (median PFS 29 months 
versus 3 months).
In summary, this is a subset analysis of the S9704 trial, one of the largest available data sets 
to prospectively address the question of upfront ASCT in patients with MYC positive 
lymphomas in the rituximab era. While our data are limited by small numbers, we observed 
a trend that MYC IHC positive and DPL patients consolidated with ASCT may have 
improved outcomes; however, nearly one-third of MYC IHC positive patients were unable to 
be randomized due to early progression or death. True FISH-defined DHL were infrequent 
even in this high-risk cohort and had a dismal prognosis. Clearly, MYC positive aggressive 
B-cell lymphomas, DHL and DPL represent unmet needs and constitute the basis of an 
intergroup study under development.
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Consort Diagram showing disposition of patients. Of the 397 patients registered for S9704, 
370 were eligible, 198 cases were evaluable for IHC analysis and 27 MYC IHC positive 
patients were identified.
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Progression free survival and overall survival of all patients with and without transplant for 
MYC IHC positive patients (Figures 2a and 2b), and DPL patients (Figures 2c and 2d) 
respectively.
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